NasdaqGS:RAREBiotechs
Ultragenyx Pharmaceutical (RARE) Is Up 5.8% After Reaffirming 2026 Outlook Despite Wider Losses – What's Changed
Ultragenyx Pharmaceutical Inc. reported past first-quarter 2026 results with revenue of US$136 million, a wider net loss of US$185 million, and reaffirmed its 2026 revenue guidance of US$730 million to US$760 million while remaining on a stated path toward profitability in 2027.
Management also highlighted potential 2026 approvals for two gene therapies and key late-stage data for its Angelman syndrome program, underscoring how clinical and regulatory milestones are central to its...